FY2025 EPS Estimates for CAPR Raised by Cantor Fitzgerald

Capricor Therapeutics Inc (NASDAQ:CAPR) – Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Capricor Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings of $1.71 per share for the year, up from their prior estimate of ($1.11). Cantor Fitzgerald has a “Overweight” rating and a $30.00 price objective on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $36.40.

Capricor Therapeutics Trading Down 1.3%

Capricor Therapeutics stock opened at $9.44 on Friday. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40. The stock has a market cap of $431.19 million, a price-to-earnings ratio of -8.91 and a beta of 0.85. The company’s 50-day moving average price is $10.70 and its two-hundred day moving average price is $13.72.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. During the same quarter in the prior year, the firm earned ($0.31) earnings per share.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Summit Investment Advisors Inc. boosted its position in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. grew its position in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at $68,000. AlphaQuest LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at $78,000. Finally, New York State Common Retirement Fund lifted its position in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 5,000 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.